Mitochondria in liver diseases

Ignazio Grattagliano, Ornella de Bari, Domenica Di Palo, Fabrizio Montecucco, Federico Carbone, Paulo J. Oliveira, David Q.H. Wang, Piero Portincasa

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Mitochondria are not only the main energy source in the hepatocytes but also play a major role in the cell redox homeostasis and maintain normal liver function including signalling pathways and the metabolism of exogenous substances. These roles assign mitochondria a gateway function in protecting hepatocyte from injury since unbalanced mitochondrial function unequivocally affects cell survival by actively causing the onset and perpetuation of liver diseases. Abnormal mitochondrial function is reported to be involved in a variety of liver diseases including drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, primary and secondary cholestasis, hemochromatosis, and Wilson's disease. These changes lead to the impairment of the electron transport chain and/or oxidative phosphorylation, which induces a decrease in oxidative degradation of many exogenous and endogenous substrates and ATP synthesis, and in general, reduces hepatocyte tolerance towards potentially damaging insults. Structural changes accompany functional impairment of mitochondria, resulting in swelling and formation of aggregates and inclusions within the mitochondrial matrix. In chronic liver diseases, adequate mitochondrial function is maintained by mitochondrial proliferation and/or by an increased activity of critical enzymes. The assessment of mitochondrial functions in vivo is a useful tool in patients with liver diseases for diagnostic and prognostic purposes in patients with liver diseases and for the evaluation of therapeutic interventions.

Original languageEnglish (US)
Title of host publicationMitochondrial Biology and Experimental Therapeutics
PublisherSpringer International Publishing
Pages91-126
Number of pages36
ISBN (Electronic)9783319733449
ISBN (Print)9783319733432
DOIs
StatePublished - Mar 21 2018

Fingerprint

Mitochondria
Liver
Liver Diseases
Hepatocytes
Chemical and Drug Induced Liver Injury
Alcoholic Liver Diseases
Hepatolenticular Degeneration
Hemochromatosis
Cholestasis
Oxidative Phosphorylation
Electron Transport
Hepatitis
Oxidation-Reduction
Cell Survival
Homeostasis
Chronic Disease
Adenosine Triphosphate
Wounds and Injuries
Metabolism
Enzymes

Keywords

  • Alcohol
  • Cholestasis
  • Fatty liver
  • Hemochromatosis
  • Hepatitis C virus
  • Nitrosative stress
  • Non-alcoholic fatty liver disease
  • Oxidative stress
  • Primary biliary cirrhosis
  • Wilson's disease

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Grattagliano, I., de Bari, O., Di Palo, D., Montecucco, F., Carbone, F., Oliveira, P. J., ... Portincasa, P. (2018). Mitochondria in liver diseases. In Mitochondrial Biology and Experimental Therapeutics (pp. 91-126). Springer International Publishing. https://doi.org/10.1007/978-3-319-73344-9_7

Mitochondria in liver diseases. / Grattagliano, Ignazio; de Bari, Ornella; Di Palo, Domenica; Montecucco, Fabrizio; Carbone, Federico; Oliveira, Paulo J.; Wang, David Q.H.; Portincasa, Piero.

Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, 2018. p. 91-126.

Research output: Chapter in Book/Report/Conference proceedingChapter

Grattagliano, I, de Bari, O, Di Palo, D, Montecucco, F, Carbone, F, Oliveira, PJ, Wang, DQH & Portincasa, P 2018, Mitochondria in liver diseases. in Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, pp. 91-126. https://doi.org/10.1007/978-3-319-73344-9_7
Grattagliano I, de Bari O, Di Palo D, Montecucco F, Carbone F, Oliveira PJ et al. Mitochondria in liver diseases. In Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing. 2018. p. 91-126 https://doi.org/10.1007/978-3-319-73344-9_7
Grattagliano, Ignazio ; de Bari, Ornella ; Di Palo, Domenica ; Montecucco, Fabrizio ; Carbone, Federico ; Oliveira, Paulo J. ; Wang, David Q.H. ; Portincasa, Piero. / Mitochondria in liver diseases. Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, 2018. pp. 91-126
@inbook{456a8ca2b4fe482886c3c986d5b4beca,
title = "Mitochondria in liver diseases",
abstract = "Mitochondria are not only the main energy source in the hepatocytes but also play a major role in the cell redox homeostasis and maintain normal liver function including signalling pathways and the metabolism of exogenous substances. These roles assign mitochondria a gateway function in protecting hepatocyte from injury since unbalanced mitochondrial function unequivocally affects cell survival by actively causing the onset and perpetuation of liver diseases. Abnormal mitochondrial function is reported to be involved in a variety of liver diseases including drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, primary and secondary cholestasis, hemochromatosis, and Wilson's disease. These changes lead to the impairment of the electron transport chain and/or oxidative phosphorylation, which induces a decrease in oxidative degradation of many exogenous and endogenous substrates and ATP synthesis, and in general, reduces hepatocyte tolerance towards potentially damaging insults. Structural changes accompany functional impairment of mitochondria, resulting in swelling and formation of aggregates and inclusions within the mitochondrial matrix. In chronic liver diseases, adequate mitochondrial function is maintained by mitochondrial proliferation and/or by an increased activity of critical enzymes. The assessment of mitochondrial functions in vivo is a useful tool in patients with liver diseases for diagnostic and prognostic purposes in patients with liver diseases and for the evaluation of therapeutic interventions.",
keywords = "Alcohol, Cholestasis, Fatty liver, Hemochromatosis, Hepatitis C virus, Nitrosative stress, Non-alcoholic fatty liver disease, Oxidative stress, Primary biliary cirrhosis, Wilson's disease",
author = "Ignazio Grattagliano and {de Bari}, Ornella and {Di Palo}, Domenica and Fabrizio Montecucco and Federico Carbone and Oliveira, {Paulo J.} and Wang, {David Q.H.} and Piero Portincasa",
year = "2018",
month = "3",
day = "21",
doi = "10.1007/978-3-319-73344-9_7",
language = "English (US)",
isbn = "9783319733432",
pages = "91--126",
booktitle = "Mitochondrial Biology and Experimental Therapeutics",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Mitochondria in liver diseases

AU - Grattagliano, Ignazio

AU - de Bari, Ornella

AU - Di Palo, Domenica

AU - Montecucco, Fabrizio

AU - Carbone, Federico

AU - Oliveira, Paulo J.

AU - Wang, David Q.H.

AU - Portincasa, Piero

PY - 2018/3/21

Y1 - 2018/3/21

N2 - Mitochondria are not only the main energy source in the hepatocytes but also play a major role in the cell redox homeostasis and maintain normal liver function including signalling pathways and the metabolism of exogenous substances. These roles assign mitochondria a gateway function in protecting hepatocyte from injury since unbalanced mitochondrial function unequivocally affects cell survival by actively causing the onset and perpetuation of liver diseases. Abnormal mitochondrial function is reported to be involved in a variety of liver diseases including drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, primary and secondary cholestasis, hemochromatosis, and Wilson's disease. These changes lead to the impairment of the electron transport chain and/or oxidative phosphorylation, which induces a decrease in oxidative degradation of many exogenous and endogenous substrates and ATP synthesis, and in general, reduces hepatocyte tolerance towards potentially damaging insults. Structural changes accompany functional impairment of mitochondria, resulting in swelling and formation of aggregates and inclusions within the mitochondrial matrix. In chronic liver diseases, adequate mitochondrial function is maintained by mitochondrial proliferation and/or by an increased activity of critical enzymes. The assessment of mitochondrial functions in vivo is a useful tool in patients with liver diseases for diagnostic and prognostic purposes in patients with liver diseases and for the evaluation of therapeutic interventions.

AB - Mitochondria are not only the main energy source in the hepatocytes but also play a major role in the cell redox homeostasis and maintain normal liver function including signalling pathways and the metabolism of exogenous substances. These roles assign mitochondria a gateway function in protecting hepatocyte from injury since unbalanced mitochondrial function unequivocally affects cell survival by actively causing the onset and perpetuation of liver diseases. Abnormal mitochondrial function is reported to be involved in a variety of liver diseases including drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, primary and secondary cholestasis, hemochromatosis, and Wilson's disease. These changes lead to the impairment of the electron transport chain and/or oxidative phosphorylation, which induces a decrease in oxidative degradation of many exogenous and endogenous substrates and ATP synthesis, and in general, reduces hepatocyte tolerance towards potentially damaging insults. Structural changes accompany functional impairment of mitochondria, resulting in swelling and formation of aggregates and inclusions within the mitochondrial matrix. In chronic liver diseases, adequate mitochondrial function is maintained by mitochondrial proliferation and/or by an increased activity of critical enzymes. The assessment of mitochondrial functions in vivo is a useful tool in patients with liver diseases for diagnostic and prognostic purposes in patients with liver diseases and for the evaluation of therapeutic interventions.

KW - Alcohol

KW - Cholestasis

KW - Fatty liver

KW - Hemochromatosis

KW - Hepatitis C virus

KW - Nitrosative stress

KW - Non-alcoholic fatty liver disease

KW - Oxidative stress

KW - Primary biliary cirrhosis

KW - Wilson's disease

UR - http://www.scopus.com/inward/record.url?scp=85046048572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046048572&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-73344-9_7

DO - 10.1007/978-3-319-73344-9_7

M3 - Chapter

AN - SCOPUS:85046048572

SN - 9783319733432

SP - 91

EP - 126

BT - Mitochondrial Biology and Experimental Therapeutics

PB - Springer International Publishing

ER -